USA

TPI’s new East Coast plant will complement its existing facility in Everett, Washington, where the company is also expanding capacity.

The deal aimed to combine Lensar’s innovative cataract surgery technologies with Alcon’s existing portfolio, potentially creating a dominant force in the femtosecond laser-assisted cataract surgery market.

Imperative Care reports that medical professionals have used its products commercially in more than 78,000 procedures, demonstrating significant market adoption and clinical trust.

The decision followed a comprehensive systematic review of published literature, which included case reports containing patient-level data and mechanistic studies that demonstrated the treatment’s potential benefits.

The platform serves multiple surgical disciplines, including arthroscopy, bariatric surgery, general surgery, gynecology, hepatopancreatobiliary transplant procedures, thoracic surgery, and urology.

The platform integrates medical devices and health information systems, creating a connected data thread with central monitoring and surveillance workflows that support clinical decision-making across encounters and over time.

The facilities house 27 specialized production suites capable of manufacturing over 2 billion tablets and capsules annually, providing substantial capacity for both clinical and commercial-scale operations.

CSL plans to incorporate its Horizon 2 production process into the expanded facility, which the company describes as a cornerstone of its global manufacturing growth strategy.

By combining its global operations with Biocare’s established commercial presence across the United States, the company aims to reach a wider customer base and strengthen its market position.

SmartHeart can cut the number of required breath-holds for basic views by up to 75%, making the examination considerably more comfortable for those being scanned.